文献速递心胸血管麻醉术前评估与围术期医学

尿NGAL/铁调素-25比值早期识别心脏术后需肾脏替代治疗的高危患者:BICARBONATE试验子研究

Urinary Neutrophil Gelatinase-Associated Lipocalin/Hepcidin-25 Ratio for Early Identification of Patients at Risk for Renal Replacement Therapy After Cardiac Surgery: A Substudy of the BICARBONATE Trial.
PubMed 文献 · Anesth Analg · 2021-01-01

该研究为BICARBONATE试验的前瞻性子研究,纳入198例体外循环心脏手术的肾脏高危患者,比较术后60分钟内尿NGAL/铁调素-25比值与尿NGAL对AKI-RRT的预测能力。结果显示比值预测AKI-RRT和院内死亡的AUC-ROC均优于NGAL,且与长期死亡率独立相关。

要点

  • 尿NGAL/铁调素-25比值预测心脏术后AKI-RRT的AUC-ROC优于单独NGAL。
  • 比值对院内死亡和长期死亡率也有预测价值。
  • 需在其他心脏手术中心验证该比值。

核心结论

  • 尿NGAL/铁调素-25比值可在心脏术后早期识别AKI-RRT高危患者,且预测性能优于NGAL。

研究设计与样本

  • BICARBONATE试验的前瞻性子研究,多中心平行随机对照试验,在三级转诊中心纳入198例体外循环心脏手术的肾脏高危患者。

主要发现

  • 发生AKI-RRT的患者(n=13)术后早期NGAL浓度高13.7倍,铁调素-25低3.3倍,NGAL/铁调素-25比值高46.9倍。

关键数值与推荐

  • 主要结局为AKI-RRT,次要结局为院内死亡和长期死亡。
  • 术后60分钟内检测尿NGAL和铁调素-25浓度并计算比值。
  • 调整变量包括Cleveland风险评分/EuroScore、主动脉阻断时间、年龄、红细胞悬液输注量和尿NGAL浓度。

临床怎么用

  • 心脏术后早期可考虑检测尿NGAL/铁调素-25比值以辅助识别AKI-RRT高危患者。
  • 该比值可能优于单独NGAL,但需在其他中心验证后推广。

局限性

  • 研究为单中心子研究,AKI-RRT事件数较少(n=13)。
  • 结论需在其他心脏手术中心确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury requiring renal replacement therapy (AKI-RRT) is strongly associated with mortality after cardiac surgery; however, options for early identification of patients at high risk for AKI-RRT are extremely limited. Early after cardiac surgery, the predictive ability for AKI-RRT even of one of the most extensively evaluated novel urinary biomarkers, neutrophil gelatinase-associated lipocalin (NGAL), appears to be only moderate. We aimed to determine whether the NGAL/hepcidin-25 ratio (urinary concentrations of NGAL divided by that of hepcidin-25) early after surgery may compare favorably to NGAL for identification of high-risk patients after cardiac surgery. METHODS: This is a prospective substudy of the BICARBONATE trial, a multicenter parallel-randomized controlled trial comparing perioperative bicarbonate infusion for AKI prevention to usual patient care. At a tertiary referral center, 198 patients at increased kidney risk undergoing cardiac surgery with cardiopulmonary bypass were included into the present study. The primary outcome measure was defined as AKI-RRT. Secondary outcomes were in-hospital mortality and long-term mortality. We compared area under the curve of the receiver operating characteristic (AUC-ROC) of urinary NGAL with that of the urinary NGAL/hepcidin-25 ratio within 60 minutes after end of surgery. We compared adjusted AUC and performed cross-validated reclassification statistics of the (logarithmic) urinary NGAL/hepcidin-25 ratio adjusted to Cleveland risk score/EuroScore, cross-clamp time, age, volume of packed red blood cells, and (logarithmic) urinary NGAL concentration. The association of the NGAL/hepcidin-25 ratio with long-term patient survival was assessed using Cox proportional hazard regression analysis adjusting for EuroScore, aortic cross-clamp time, packed red blood cells and urinary NGAL. RESULTS: Patients with AKI-RRT (n = 13) had 13.7-times higher NGAL and 3.3-times lower hepcidin-25 concentrations resulting in 46.9-times higher NGAL/hepcidin-25 ratio early after surgery compared to patients without AKI-RRT. The NGAL/hepcidin-25 ratio had higher AUC-ROC compared with NGAL for risk of AKI-RRT and in-hospital mortality (unadjusted AUC-ROC difference 0.087, 95% confidence interval [CI], 0.036-0.138, P < .001; 0.082, 95% CI, 0.018-0.146, P = .012). For AKI-RRT, the NGAL/hepcidin-25 ratio increased adjusted category-free net reclassification improvement (cfNRI; 0.952, 95% CI, 0.437-1.468; P < .001) and integrated discrimination improvement (IDI; 0.040, 95% CI, 0.008-0.073; P = .016) but not AUC difference. For in-hospital mortality, the ratio improved AUC of the reference model (AUC difference 0.056, 95% CI, 0.003-0.108; P = .037) and cfNRI but not IDI. The urinary NGAL/hepcidin-25 ratio remained significantly associated with long-term mortality after adjusting for the model covariates. CONCLUSIONS: The urinary NGAL/hepcidin-25 ratio appears to early identify high-risk patients and outperform NGAL after cardiac surgery. Confirmation of our findings in other cardiac surgery centers is now needed.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Elitok S, Kuppe H, Devarajan P, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin/Hepcidin-25 Ratio for Early Identification of Patients at Risk for Renal Replacement Therapy After Cardiac Surgery: A Substudy of the BICARBONATE Trial. Anesth Analg. 2021. PMID: 34543256. doi:10.1213/ANE.0000000000005741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。